{"preliminary_commentary":{"by_channel":{"x_thread":5,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["saruparib"]],"indication":"metastatic castration-sensitive prostate cancer","name":"EvoPAR-Prostate01","nct_id":"NCT06120491","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=evopar-prostate01-nct06120491. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"EvoPAR-PR01","arms":[{"description":"Saruparib (AZD5305) + physician's choice NHA (Abiraterone, Darolutamide, or Enzalutamide)","label":"Arm 1: Saruparib (AZD5305) + Physician's Choice NHA","type":"EXPERIMENTAL"},{"description":"Placebo + physician's choice NHA (Abiraterone, Darolutamide, or Enzalutamide)","label":"Arm 2: Placebo + Physician's Choice NHA","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2031-04-30","type":"ESTIMATED"},"conditions":["Metastatic Castration-Sensitive Prostate Cancer"],"enrollment":{"count":1898,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Saruparib","otherNames":["AZD5305"],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"},{"name":"Abiraterone Acetate","otherNames":["Zytiga"],"type":"DRUG"},{"name":"Darolutamide","otherNames":["Nubeqa"],"type":"DRUG"},{"name":"Enzalutamide","otherNames":["Xtandi"],"type":"DRUG"}],"last_update":"2026-07-29","lead_sponsor":"AstraZeneca","official_title":"A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-09-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Radiographic Progression-Free Survival (rPFS)","timeFrame":"Up to approximately 50 months"}],"references":[{"citation":"Azad AA, Agarwal N, Armstrong AJ, Hellmis E, Sugimoto M, Urun Y, Xing N, Aregay M, Lima J, Meulendijks D, Chi KN. Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01. Future Oncol. 2026 Apr;22(10):1153-1163. doi: 10.1080/14796694.2026.2655433. Epub 2026 Apr 14.","pmid":"41979035","type":"DERIVED"}],"start_date":{"date":"2023-11-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents","url":"https://clinicaltrials.gov/study/NCT06120491"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/evopar-prostate01-nct06120491"}